The First International Symposium on Pheochromocytoma, held in October 2005, included discussions about developments concerning these rare catecholamine-producing tumors. Recommendations were made ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...

The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.

Patients diagnosed with pheochromocytoma or paraganglioma, tumors that form within certain endocrine tissues, such as the adrenal glands, may have abnormal endocrine activity due to the synthesis ...

Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

After more tests, Kanellis was diagnosed with a rare tumor on the adrenal glands; so rare the diagnosis rate is approximately 8 out of every 1,000,000 people. A pheochromocytoma tumor, which ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA ...

which is referred to as an intra-abdominal pheochromocytoma. “The tumor was invading into the vena cava, which is a large, important blood vessel,” Dr. Haney says. “It was determined that ...

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

Pathologic examination should distinguish primary or metastatic pheochromocytomas and paragangliomas from other endocrine or nonendocrine tumors and flag tumors with features suggestive of ...

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.